https://scholars.lib.ntu.edu.tw/handle/123456789/634517
標題: | The study of a novel CDK8 inhibitor E966-0530-45418 that inhibits prostate cancer metastasis in vitro and in vivo | 作者: | Ho, Tai-Yuan Sung, Ting-Yi Pan, Shiow-Lin Huang, Wei-Jan Hsu, Kai-Cheng Hsu, Jui-Yi Lin, Tony Eight Hsu, Chia-Ming CHIA-RON YANG |
關鍵字: | Cyclin-dependent kinase 8; Epithelial-to-mesenchymal transition; Mediator complex; Metastasis; Prostate cancer | 公開日期: | 六月-2023 | 卷: | 162 | 起(迄)頁: | 114667 | 來源出版物: | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie | 摘要: | Prostate cancer is a prevalent malignancy among men globally, and androgen deprivation therapy is the conventional first-line treatment for metastatic prostate cancer. While androgen deprivation therapy is efficacious in castration-sensitive prostate cancer, it remains less effective in castration-resistant cases. Transcriptional dysregulation is a well-established hallmark of cancer, and targeting proteins involved in transcriptional regulation, such as cyclin-dependent kinase 8 (CDK8), has become an attractive therapeutic strategy. CDK8, a nuclear serine-threonine kinase, is a key component of the mediator complex and plays a critical role in transcriptional regulation. Recent studies have highlighted the promising role of CDK8 as a target in the treatment of metastatic prostate cancer. Our study assessed the efficacy of a novel CDK8 inhibitor, E966-0530-45418, which exhibited potent CDK8 inhibition (IC50 of 129 nM) and high CDK8 selectivity. Treatment with E966-0530-45418 significantly inhibited prostate cancer cell migration and epithelial-to-mesenchymal transition (EMT) at both the RNA and protein levels. Further mechanistic analysis indicated that E966-0530-45418 suppresses prostate cancer metastasis by decreasing CDK8 activity and inhibiting TGF-β1-mediated Smad3/RNA polymerase II linker phosphorylation and Akt/GSK3β/β-catenin signaling. The results in animal model also showed that E966-0530-45418 exhibited anti-metastatic properties in vivo. Our study demonstrated that E966-0530-45418 has great therapeutic potential in the treatment of metastatic prostate cancer. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/634517 | ISSN: | 07533322 | DOI: | 10.1016/j.biopha.2023.114667 |
顯示於: | 藥學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。